Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Eagle PharmaceuticalsAC ImmuneBasilea PharmaceuticaGeronUrovant Sciences
SymbolNASDAQ:EGRXNASDAQ:ACIUOTCMKTS:BPMUFNASDAQ:GERNNASDAQ:UROV
Price Information
Current Price$44.27$6.73$50.20$1.47$16.24
52 Week RangeHoldBuyBuyBuyHold
MarketRank™
Overall Score1.21.30.61.40.7
Analysis Score1.03.50.03.51.0
Community Score2.92.42.22.72.0
Dividend Score0.00.00.00.00.0
Ownership Score1.70.00.00.80.0
Earnings & Valuation Score0.60.60.60.00.6
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyHold
Consensus Price Target$46.00$16.00N/A$4.20$16.17
% Upside from Price Target3.91% upside137.74% upsideN/A185.71% upside-0.45% downside
Trade Information
Market Cap$585.12 million$484.14 million$539.18 million$468.24 million$531.75 million
Beta0.740.821.51.52.36
Average Volume124,162881,5171223,697,983114,469
Sales & Book Value
Annual Revenue$195.89 million$111.75 million$135.28 million$460,000.00N/A
Price / Sales2.994.333.991,017.91N/A
Cashflow$1.61 per share$0.75 per shareN/AN/AN/A
Price / Cash27.498.97N/AN/AN/A
Book Value$13.11 per share$4.06 per share($7.88) per share$0.68 per share($1.90) per share
Price / Book3.381.66-6.372.16N/A
Profitability
Net Income$14.31 million$45.74 million$-22,490,000.00$-68,550,000.00$-146,740,000.00
EPS$1.38$0.60($2.09)($0.36)($4.71)
Trailing P/E Ratio126.49N/AN/AN/AN/A
Forward P/E Ratio147.57N/A185.94N/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins2.65%-392.56%N/A-21,631.02%N/A
Return on Equity (ROE)8.50%-23.88%N/A-43.76%N/A
Return on Assets (ROA)5.44%-21.85%N/A-37.24%-162.90%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.16%N/AN/A0.10%N/A
Current Ratio3.60%18.10%4.26%9.60%2.91%
Quick Ratio3.45%18.10%3.91%9.60%2.91%
Ownership Information
Institutional Ownership Percentage95.12%27.68%N/A55.51%18.44%
Insider Ownership Percentage21.10%N/AN/A7.70%2.70%
Miscellaneous
Employees1081251575370
Shares Outstanding13.22 million71.94 million10.74 million318.53 million32.74 million
Next Earnings Date5/10/2021 (Estimated)5/3/2021 (Estimated)5/18/2021 (Estimated)5/27/2021 (Estimated)6/17/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
Vibegron officially launched in US OAB marketVibegron officially launched in US OAB market
urologytimes.com - April 13 at 5:50 PM
Urovant Sciences Ltd. (NASDAQ:UROV) Short Interest Up 67.3% in MarchUrovant Sciences Ltd. (NASDAQ:UROV) Short Interest Up 67.3% in March
americanbankingnews.com - March 30 at 10:02 AM
Urovant Taken Private as Sumitovant Deal ClosesUrovant Taken Private as Sumitovant Deal Closes
ocbj.com - March 29 at 2:04 PM
Sumitovant Biopharma Completes Acquisition of Urovant SciencesSumitovant Biopharma Completes Acquisition of Urovant Sciences
finance.yahoo.com - March 29 at 8:20 AM
Urovant Sciences (NASDAQ:UROV) Sees Strong Trading VolumeUrovant Sciences (NASDAQ:UROV) Sees Strong Trading Volume
americanbankingnews.com - March 26 at 12:02 PM
Bicycle Therapeutics Ltd. ADRBicycle Therapeutics Ltd. ADR
wsj.com - March 21 at 8:49 AM
Sumitovant Biopharmas Portfolio of Innovative Companies Achieve Significant Clinical and Corporate Milestones in its Third Quarter of OperationSumitovant Biopharma's Portfolio of Innovative Companies Achieve Significant Clinical and Corporate Milestones in its Third Quarter of Operation
marketwatch.com - March 4 at 1:40 PM
Overactive Bladder (OAB) Treatment Market Value Anticipated To Reach US$ 6.5 Billion By 2027: Acumen Research and ConsultingOveractive Bladder (OAB) Treatment Market Value Anticipated To Reach US$ 6.5 Billion By 2027: Acumen Research and Consulting
finance.yahoo.com - March 3 at 10:36 PM
NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: Urovant Sciences Ltd. (Nasdaq - UROV), Cubic Corporation (NYSE - CUB), CoreLogic, Inc. (NYSE - CLGX)NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: Urovant Sciences Ltd. (Nasdaq - UROV), Cubic Corporation (NYSE - CUB), CoreLogic, Inc. (NYSE - CLGX)
finance.yahoo.com - February 13 at 1:10 PM
Urovant Sciences gets DSMB recommendation to continue phase 2a study of URO-902to treat overactive bladder & urge urinary incontinenceUrovant Sciences gets DSMB recommendation to continue phase 2a study of URO-902to treat overactive bladder & urge urinary incontinence
pharmabiz.com - February 13 at 8:10 AM
Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and SafetyUrovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety
bloomberg.com - February 12 at 9:33 AM
Novel Treatment for Patients with Overactive Bladder, Vibegron First Oral Branded OAB Medication ApprovedNovel Treatment for Patients with Overactive Bladder, Vibegron First Oral Branded OAB Medication Approved
urotoday.com - January 22 at 8:40 AM
ALERT: Halper Sadeh LLP Reminds Investors of Its Ongoing Merger Investigations; Shareholders are Encouraged to Contact the Firm – CBMG, CGIX, UROVALERT: Halper Sadeh LLP Reminds Investors of Its Ongoing Merger Investigations; Shareholders are Encouraged to Contact the Firm – CBMG, CGIX, UROV
finance.yahoo.com - January 17 at 8:54 PM
GEMTESA® (vibegron) Receives U.S. FDA Approval for the Treatment of Patients with Overactive Bladder (OAB)GEMTESA® (vibegron) Receives U.S. FDA Approval for the Treatment of Patients with Overactive Bladder (OAB)
urotoday.com - January 5 at 1:12 AM
Lifshitz Law Firm, P.C. Announces Investigation of CBMG, CBLI, WORK, and UROVLifshitz Law Firm, P.C. Announces Investigation of CBMG, CBLI, WORK, and UROV
finance.yahoo.com - January 3 at 5:59 PM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers – UROV, EIGI, SNCA, CLCTSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers – UROV, EIGI, SNCA, CLCT
finance.yahoo.com - December 30 at 12:34 PM
Urovant Sciences Announces U.S. FDA Approval of GEMTESA (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)Urovant Sciences Announces U.S. FDA Approval of GEMTESA (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
wallstreet-online.de - December 25 at 12:59 AM
Vivek Ra­maswamys van­t brain­chil­dren keep bear­ing fruit with Urovan­ts FDA nod for in­con­ti­nence med vibegronVivek Ra­maswamy's 'van­t' brain­chil­dren keep bear­ing fruit with Urovan­t's FDA nod for in­con­ti­nence med vibegron
endpts.com - December 25 at 12:59 AM
FDA approves Urovants Gemtesa as overactive bladder treatmentFDA approves Urovant's Gemtesa as overactive bladder treatment
bioworld.com - December 24 at 2:51 PM
Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
finance.yahoo.com - December 23 at 5:23 PM
The Week Ahead In Biotech: Light Calendar In Abbreviated Week Features 1 IPO, 2 FDA DecisionsThe Week Ahead In Biotech: Light Calendar In Abbreviated Week Features 1 IPO, 2 FDA Decisions
benzinga.com - December 19 at 7:10 PM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies – EIGI, XLNX, UROV, HDSSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies – EIGI, XLNX, UROV, HDS
finance.yahoo.com - December 16 at 12:13 PM
Is Urovant Sciences Ltd. (UROV) A Good Stock To Buy?Is Urovant Sciences Ltd. (UROV) A Good Stock To Buy?
finance.yahoo.com - December 3 at 3:28 AM
SHAREHOLDER ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Investors are Encouraged to Contact the Firm - GV, HDS, UROV, TNAVSHAREHOLDER ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Investors are Encouraged to Contact the Firm - GV, HDS, UROV, TNAV
finance.yahoo.com - November 30 at 9:08 PM
WeissLaw LLP Reminds CCR, TCO, UROV, and PTI Shareholders About Its Ongoing InvestigationsWeissLaw LLP Reminds CCR, TCO, UROV, and PTI Shareholders About Its Ongoing Investigations
finance.yahoo.com - November 30 at 9:08 PM
DateCompanyBrokerageAction
4/20/2020Eagle PharmaceuticalsCantor FitzgeraldReiterated Rating
3/25/2020Eagle PharmaceuticalsRoyal Bank of CanadaReiterated Rating
4/24/2019Eagle PharmaceuticalsMizuhoReiterated Rating
10/31/2018Eagle PharmaceuticalsPiper Jaffray CompaniesDowngrade
3/30/2021AC ImmuneHC WainwrightBoost Price Target
2/1/2019AC ImmuneUBS GroupDowngrade
11/12/2018AC ImmuneSVB LeerinkInitiated Coverage
5/3/2018AC ImmuneCredit Suisse GroupSet Price Target
2/17/2021GeronB. RileyReiterated Rating
8/3/2020GeronStifel NicolausInitiated Coverage
6/17/2020GeronNeedham & Company LLCReiterated Rating
4/3/2020GeronBTIG ResearchLower Price Target
9/27/2018GeronS&P Equity ResearchLower Price Target
7/5/2018Geron(FBRC)Initiated Coverage
11/16/2020Urovant SciencesJPMorgan Chase & Co.Reiterated Rating
11/13/2020Urovant SciencesJefferies Financial GroupDowngrade
3/15/2019Urovant SciencesSunTrust BanksInitiated Coverage
10/22/2018Urovant SciencesCowenInitiated Coverage
(Data available from 4/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.